Abstract
Molecular cancer treatments are often geared at interfering with signaling pathways that govern cell fate or proliferation. These therapeutic strategies target kinases, the signal transducers in the cell. This approach remains challenging because kinases are evolutionarily and therefore structurally related and thus kinase inhibitors often lack the required specificity, which may lead to toxic or health-threatening side effects. This chapter illustrates the power of the wrapping concept in engineering safer kinase inhibitors, thus unraveling a rational approach to fulfill this therapeutic imperative. The focus of this chapter is the redesign of the anticancer drug imatinib (Gleevec) used to treat chronic myeloid leukemia, where its primary target is the chimeric Bcr-Abl kinase, as well as certain solid tumors based on its impact on the C-Kit kinase. Imatinib also has potentially cardiotoxic effects traceable to its impact on the Abl kinase in off-target cells, and immunosuppressive effects through its impact on Lck. This chapter describes a wrapping modification of imatinib purposely designed to prevent inhibitory impact against Abl (and Bcr-Abl) and Lck, to re-focus the impact towards C-Kit and to promote inhibition of an additional target, JNK, required to reinforce the prevention of cardiotoxicity and recognized as a target of significant therapeutic interest in its own right. The molecular blueprint for target discrimination, described in Chaps. 4 and 6, is now validated through assays that span a vast testing ground, from in silico assessment and test-tube probes to animal models. The findings surveyed in this chapter identify the wrapping-based re-engineered imatinib as an agent to treat gastrointestinal stromal tumors and possibly ovarian cancer with reduced side effects, thereby illustrating the therapeutic impact of the wrapping technology.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov. 2003;2:296–313.
Levitski A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science. 1995;267:1782–8.
Tibes R, Trent J, Kurzrock R. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu Rev Pharmacol Toxicol. 2005;45:357–84.
Gibbs J, Oliff A. Pharmaceutical research in molecular oncology. Cell. 1994;79:193–8.
Donato NJ, Talpaz M. Clinical use of tyrosine kinase inhibitors: therapy for chronic myelogenous leukemia and other cancers. Clin Cancer Res. 2000;6:2965–6.
Fabian MA, Biggs WH, Treiber DK, et al. A small molecule kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005;23:329–36.
Gambacorti-Passerini C, le Coutre P, Mologni L, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis. 1997;23:380–94.
Schindler T, Bornmann W, Pellicena P, et al. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science. 2000;289:1938–42.
Attoub S, Rivat C, Rodrigues S, et al. The c-kit tyrosine kinase inhibitor STI-571 for colorectal cancer therapy. Cancer Res. 2002;62:4879–83.
DeMatteo RP. The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol. 2002;9:831–9.
Skene RJ, Kraus ML, Scheibe DN, et al. Structural basis for autoinhibition and STI-571 inhibition of C-kit Tyrosine kinase. J Biol Chem. 2004;279:31655–63.
Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-Kit oncoprotein: biological and clinical implications. Oncogene. 2001;20:5054–8.
Chen JP, Zhang X, Fernández A. Molecular basis for specificity in the druggable kinome: sequence-based analysis. Bioinformatics. 2007;23:563–72.
Fernández A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, Wulf S, Shavrin A, Qin C, Ma J, Trent J, Lin Y, Han HD, Mangala LS, Bankson JA, Gelovani J, Samarel A, Bornmann W, Sood AK, Lopez-Berestein G. An anticancer c-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest. 2007;117:4044–54.
Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12:908–16.
Druker BJ. Molecularly targeted therapy: have the floodgates opened? Oncologist. 2004;9:357–60.
Vivas-Mejia P, Benito JM, Fernández A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, Sanguino A, Peng Z, Sood AK, Lopez-Berestein G. c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res. 2010;16:184–94.
Fernández A, Scheraga HA. Insufficiently dehydrated hydrogen bonds as determinants of protein interactions. Proc Natl Acad Sci U S A. 2003;100:113–8.
Barker S, Kassel D, Weigl D, et al. Characterization of pp60c-src tyrosine kinase activities using a continuous assay: autoactivation of the enzyme is an intermolecular autophosphorylation process. Biochemistry. 1995;34:14843–51.
Songyang Z, Carraway KL, Eck M, et al. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature. 1995;373:536–9.
Clarkson B, Strife A, Wisniewski D, Lambek CL, Liu C. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategy. Leukemia. 2003;17:1211–62.
Baines CP, Molkentin JD. Stress signaling pathways that modulate cardiac myocyte apoptosis. J Mol Cell Cardiol. 2005;38:47–62.
Prenen H, Deroose C, Vermaelen P, Sciot R, Debiec-Rychter M. Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to Imatinib by small animal positron emission tomography. Anticancer Res. 2006;26:1247–52.
Scheuermann-Freestone M, Simon Freestone N, Langenickel T, et al. A new model of congestive heart failure in the mouse due to chronic volume overload. Eur J Heart Fail. 2001;3:535–43.
Theoharides T. Mast cells and pancreatic cancer. N Engl J Med. 2008;358:1860–1.
Huang B, Lei Z, Zhang GM, Li D, Song C, Li B, Liu Y, Yuan Y, Unkeless J, Xiong H, Feng ZH. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood. 2008;112:1269–79.
Kao J, Ko EC, Eisenstein S, Sikora AG, Fu S, Chen SH. Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hemat. 2011;77:12–9.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Fernández, A. (2016). Epistructural Re-engineering of Imatinib to Eliminate Adverse Side Effects. In: Physics at the Biomolecular Interface. Soft and Biological Matter. Springer, Cham. https://doi.org/10.1007/978-3-319-30852-4_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-30852-4_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-30851-7
Online ISBN: 978-3-319-30852-4
eBook Packages: Physics and AstronomyPhysics and Astronomy (R0)